2026 ADA Standards of Care: Updates, Critiques, and the "Slow Drift" of Guidance

Review of the 2026 ADA Standards of Care

• 💡 The 2026 ADA Standards of Care have been released, prompting a review of key updates and a critique of the guidance's pace.
• 🎯 The discussion highlights a perceived "slow drift" in official guidance compared to real-world diabetes management practices.

Key Updates and New Recommendations

• 🚀 GLP-1 receptor agonists are now explicitly listed as recommended treatment options for obesity in individuals with Type 1 diabetes.
• ⚙️ The requirement for C-Peptide levels or antibody presence has been removed for initiating insulin pumps or AID systems, improving technology access.
• 🏥 A significant new standard mandates that basal insulin should never be held for patients with Type 1 diabetes while hospitalized.
• 🧑‍💼 New language supports reasonable accommodations for adults using diabetes technology (pumps/CGMs) in the workplace.
• ⚠️ A new warning advises against cannabis use for those at risk of DKA, citing concerns about cannabis hyperemesis syndrome.

Critiques of Guidance Pace and Implementation

• ⏳ The standards are criticized for lagging behind effective real-world management, with some concepts discussed for years before appearing in official guidance.
• 📉 The A1C target of under 7 for adults and 7.5 for children remains unchanged, despite advancements in diabetes management.
• 🗣️ There's a concern that official guidance can create a